ChiCTR1800018070.
| Study name | Clinical study of rehoci combined with long‐acting octreotide in reducing the risk of rebleeding in patients with cirrhosis and portal hypertension |
| Methods | Trial to determine if rifaximin (rehoci) has a beneficial effect on the risk of rebleeding in participants with cirrhosis and portal hypertension when used as monotherapy or when combined with octreotide. If data are reported on hepatic encephalopathy then we will be able to compare outcomes in the rifaximin monotherapy and placebo groups. Blinding not stated. |
| Participants | Planned recruitment sample size: 80 people. People aged 18 to 75 years of any gender with cirrhosis, portal hypertension, and confirmed oesophageal varices of any cause. Participants must be classified as Child‐Pugh grade B or C for over 1 month Participants will be excluded if suffering from moderate to severe hepatic encephalopathy "in recent months". |
| Interventions | Participants will be randomised to one of four groups of 20 participants each:
Dose and timings not stated |
| Outcomes | CT, MRI, ultrasonography, liver function, blood ammonia |
| Starting date | 1 January 2019 to 30 June 2022 |
| Contact information | Guan Jiao, tel: +86 18817821667; email: 0727guanjiao@163.com |
| Notes | Last update 28 August 2018, as 'not yet recruiting' This study might allow outcomes of interest to be compared between the rifaximin and placebo group. |